Thalia Therapeutics Plc (AIM:THAT)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.5750
-0.0500 (-8.00%)
Apr 15, 2026, 4:21 PM GMT
Market Cap4.79M +185.2%
Revenue (ttm)7.07K +20.6%
Net Income-1.10M
EPS-0.00
Shares Out832.28M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume605,480
Average Volume1,905,151
Open0.6000
Previous Close0.6250
Day's Range0.5500 - 0.6500
52-Week Range0.3500 - 1.0000
Beta0.52
RSI62.51
Earnings DateJun 25, 2026

About Thalia Therapeutics

Thalia Therapeutics Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1979
Employees 4
Stock Exchange London Stock Exchange AIM
Ticker Symbol THAT
Full Company Profile

Financial Performance

In 2024, Thalia Therapeutics's revenue was 7,282, an increase of 272.86% compared to the previous year's 1,953. Losses were -1.06 million, -16.60% less than in 2023.

Financial Statements